X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs CIPLA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES CIPLA DIVIS LABORATORIES/
CIPLA
 
P/E (TTM) x 33.3 37.6 88.7% View Chart
P/BV x 5.4 3.9 140.0% View Chart
Dividend Yield % 0.9 0.3 275.7%  

Financials

 DIVIS LABORATORIES   CIPLA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
CIPLA
Mar-17
DIVIS LABORATORIES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,222622 196.5%   
Low Rs784458 171.1%   
Sales per share (Unadj.) Rs153.1181.9 84.2%  
Earnings per share (Unadj.) Rs39.912.9 310.4%  
Cash flow per share (Unadj.) Rs44.629.3 152.1%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.00.4 269.2%  
Book value per share (Unadj.) Rs201.8155.7 129.6%  
Shares outstanding (eoy) m265.47804.51 33.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.63.0 220.6%   
Avg P/E ratio x25.142.0 59.8%  
P/CF ratio (eoy) x22.518.4 122.1%  
Price / Book Value ratio x5.03.5 143.3%  
Dividend payout %25.015.5 161.1%   
Avg Mkt Cap Rs m266,266434,516 61.3%   
No. of employees `0009.723.0 42.2%   
Total wages/salary Rs m4,68726,338 17.8%   
Avg. sales/employee Rs Th4,175.06,349.1 65.8%   
Avg. wages/employee Rs Th481.51,143.0 42.1%   
Avg. net profit/employee Rs Th1,089.3449.3 242.4%   
INCOME DATA
Net Sales Rs m40,643146,302 27.8%  
Other income Rs m7492,287 32.7%   
Total revenues Rs m41,392148,589 27.9%   
Gross profit Rs m14,46024,758 58.4%  
Depreciation Rs m1,23313,229 9.3%   
Interest Rs m231,594 1.4%   
Profit before tax Rs m13,95312,222 114.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,3491,798 186.3%   
Profit after tax Rs m10,60410,354 102.4%  
Gross profit margin %35.616.9 210.2%  
Effective tax rate %24.014.7 163.2%   
Net profit margin %26.17.1 368.7%  
BALANCE SHEET DATA
Current assets Rs m40,10587,370 45.9%   
Current liabilities Rs m6,59533,081 19.9%   
Net working cap to sales %82.537.1 222.2%  
Current ratio x6.12.6 230.3%  
Inventory Days Days11987 136.3%  
Debtors Days Days8162 129.5%  
Net fixed assets Rs m19,995111,567 17.9%   
Share capital Rs m5311,609 33.0%   
"Free" reserves Rs m53,043123,645 42.9%   
Net worth Rs m53,574125,254 42.8%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m61,585209,532 29.4%  
Interest coverage x618.48.7 7,134.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.70.7 94.5%   
Return on assets %17.35.7 302.6%  
Return on equity %19.88.3 239.4%  
Return on capital %26.18.5 306.9%  
Exports to sales %034.2 0.0%   
Imports to sales %25.28.3 302.6%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs m10,25912,203 84.1%   
Fx inflow Rs m35,38451,066 69.3%   
Fx outflow Rs m10,39917,678 58.8%   
Net fx Rs m24,98533,388 74.8%   
CASH FLOW
From Operations Rs m11,49323,824 48.2%  
From Investments Rs m-11,372-13,127 86.6%  
From Financial Activity Rs m-93-13,239 0.7%  
Net Cashflow Rs m28-2,478 -1.1%  

Share Holding

Indian Promoters % 52.0 16.0 325.0%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 11.8 12.2 96.7%  
FIIs % 19.0 23.7 80.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.2 26.2 65.6%  
Shareholders   31,796 161,166 19.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 19, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS